Axiomer Technology - Therapeutic oligonucleotides for directing site-specific A-to-I editing by endogenous ADAR enzymes
Axiomer® technology can introduce precise A-to-I modifications in endogenous RNA transcripts. This RNA editing enables e.g. the correction of G-to-A mutations, since inosines are interpreted as guanosines. RNA editing is achieved by Axiomer® Editing Oligonucleotides (EONs) that can direct site-specific deamination by endogenous ADARs (Adenosine Deaminases Acting on RNA). Rational EON design relies both on computational and empirical approaches to achieve high potency and drug-like properties.
Presented at TIDES Europe 2018 by Antti Aalto - ProQR Therapeutics
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
Axiomer platform presentation highlighting the potential of Editing Oligonucleotides (EONs) to address liver originated disorders. Presented at the RNA Editing Gordon Research Conference on March 23, 2023 by Gerard Platenburg - ProQR Therapeutics.
This virtual event on March 29, 2023 featured presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, detailed the initial pipeline targets, and provided guidance on the advancement of programs toward the clinic. ProQR also reported its 2022 year-end financials and the extension of its cash runway guidance.